Abstract
Development of Expressed Sequence Tag-Single Nucleotide Polymorphism Markers in Swimming Crab, Portunus trituberculatus
Highlights
Technology Affiliated Hospital, 73 Jianshe Road, Tangshan, 063000, China 3Medical intensive care unit (ICU), Peking Union Medical College Hospital, Beijing, 100730, China le ABSTRACT rtic Opioids are commonly required to relieve pain in critically ill patients, especially for those under mechanical ventilation (MV)
Data analysis will adopt an intention-to-treat approach. This trial will demonstrate the probability that remifentanil can reduce the duration of MV in long-term ventilated patients in critically ill patients compared to fentanyl
Mechanical ventilation 1140 (685-1542) 1110 (795-2670) 0.79 we obtained the average dosage per patient per day for every drug. price was taken into account, costs of analgesic and sedative agent were derived
Summary
Remifentanil Versus Fentanyl in Mechanically Ventilated Critically Ill Patients: Study Protocol for a Randomized Controlled Study. Secondary t outcomes include the duration of extubation, costs and length of stay (LOS) in ICU, dose adjustment time, analgesic and sedative agent costs, short-term mortality, and adverse events potentially relevant to irs the study drugs. Data analysis will adopt an intention-to-treat approach This trial will demonstrate the probability that remifentanil can reduce the duration of MV in long-term ventilated patients in critically ill patients compared to fentanyl. IPAD recommends that intravenous opioids be considered as n the first-line drug class of choice to treat non-neuropathic O pain in critically ill patients (Barr et al, 2013), while in reduction in duration of mechanical ventilation (MV) (Karabinis et al, 2004). Remifentanil has not yet been extensively accepted by ICU physicians, especially in patients who undergo long-term mechanical ventilation. Exclusion criteria were (i) basic conditions (such as alcohol abuse; (ii) after tranquilizing for more than
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
